HomeCompareELYM vs EPRT

ELYM vs EPRT: Dividend Comparison 2026

ELYM yields 39.14% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELYM wins by $157.8K in total portfolio value
10 years
ELYM
ELYM
● Live price
39.14%
Share price
$5.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$221.2K
Annual income
$36,710.06
Full ELYM calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ELYM vs EPRT

📍 ELYM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELYMEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELYM + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELYM pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELYM
Annual income on $10K today (after 15% tax)
$3,326.81/yr
After 10yr DRIP, annual income (after tax)
$31,203.55/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ELYM beats the other by $20,288.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELYM + EPRT for your $10,000?

ELYM: 50%EPRT: 50%
100% EPRT50/50100% ELYM
Portfolio after 10yr
$142.3K
Annual income
$24,775.39/yr
Blended yield
17.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ELYM
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
25.2
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELYM buys
0
EPRT buys
0
No recent congressional trades found for ELYM or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELYMEPRT
Forward yield39.14%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$221.2K$63.4K
Annual income after 10y$36,710.06$12,840.73
Total dividends collected$165.4K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ELYM vs EPRT ($10,000, DRIP)

YearELYM PortfolioELYM Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$14,614$3,913.89$11,205$505.18+$3.4KELYM
2$20,982$5,345.54$12,672$682.46+$8.3KELYM
3$29,624$7,172.93$14,490$930.48+$15.1KELYM
4$41,162$9,464.62$16,786$1,282.69+$24.4KELYM
5$56,334$12,290.65$19,753$1,791.56+$36.6KELYM
6$75,998$15,720.42$23,677$2,541.64+$52.3KELYM
7$101,138$19,820.29$29,008$3,672.99+$72.1KELYM
8$132,869$24,651.24$36,463$5,425.08+$96.4KELYM
9$172,437$30,266.60$47,238$8,221.57+$125.2KELYM
10$221,217$36,710.06$63,385$12,840.73+$157.8KELYM

ELYM vs EPRT: Complete Analysis 2026

ELYMStock

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Full ELYM Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ELYM vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELYM vs SCHDELYM vs JEPIELYM vs OELYM vs KOELYM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.